Panic among overweight individuals using Mounjaro as price surge looms imminently
In the UK, a significant price hike for the weight loss injection Mounjaro (tirzepatide) is set to take effect from September 1st, 2025. This increase may substantially impact private patients, potentially making treatment less affordable for some[1][2].
However, it is important to note that the price rise does not affect the NHS cost or access, as agreements with the NHS ensure continued supply and patient access at negotiated prices[1]. For NHS patients, access to Mounjaro started in June 2025, and further weight management pilot programs with government and manufacturer funding aim to expand support[1].
For private patients concerned about affordability, alternative options such as Wegovy (semaglutide), another licensed weight-loss injection, may be considered. Wegovy tends to be somewhat more cost-effective, with prices around £109 compared to the new higher Mounjaro prices, and shows comparable weight loss effectiveness in clinical trials (Wegovy up to 21% weight loss vs. Mounjaro up to 20%)[3]. Patients should consult healthcare professionals before switching, as the medications have different active ingredients and side-effect profiles (e.g., injection site reactions and impacts on oral contraceptives)[3].
Dr Leyla Hannbeck of the Independent Pharmacies Association advises against buying tirzepatide in bulk, and Dr Sophie Dix from MedExpress pharmacy states that patients are fearful of being unable to afford treatment due to the price hike. Pharmacies have reported an influx of phone calls from anxious patients trying to stock up on tirzepatide. Sandeep Dhami from MW Phillips Chemists in the West Midlands reports that patients are going to pharmacies angry and upset at the price hike[4].
Dr Leyla Hannbeck suggests that patients speak to their local pharmacist about alternatives, and patients are encouraged to consult with their healthcare provider for guidance on fat jab injections and potential alternatives[4]. It is estimated that more than a million people in the UK are buying fat jab injections privately[5].
Abdal Alvi at Simple Online Pharmacy advises against being tempted by sellers on social media. Boots chemist will review its weight loss services in light of the price hike for tirzepatide[5]. Additionally, the Independent Pharmacies Association has members who provide fat jab injections[5].
Support programs and funding are being developed to improve weight management access in the NHS setting[1]. With the price hike for Mounjaro looming, it is crucial for private patients to carefully consider their clinical response, costs, and treatment options in consultation with their healthcare provider.
- While the price hike for Mounjaro (tirzepatide) may challenge private patients' ability to afford treatment, alternative options in health-and-wellness like Wegovy (semaglutide), a licensed weight-loss injection, could be considered due to its comparative cost-effectiveness and comparable weight loss effectiveness.
- In the context of the forthcoming price increase for Mounjaro, it is essential for private patients to seek guidance from their healthcare providers regarding nutrition, medical-conditions, and other alternatives in weight-management programs to ensure they maintain optimal health while finding a suitable treatment option.
